| scholarly article | Q13442814 |
| P50 | author | Claudio Napoli | Q37836844 |
| Teresa Infante | Q59548496 | ||
| P2093 | author name string | Antonietta Picascia | |
| P2860 | cites work | Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants | Q33460691 |
| Using real data for a virtual crossmatch | Q33467644 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Humoral theory of transplantation | Q35142603 | ||
| HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation | Q36751659 | ||
| Defining unacceptable HLA antigens | Q37236970 | ||
| Post-transplantation antibody monitoring and HLA antibody epitope identification | Q37240392 | ||
| Review article: Luminex technology for HLA antibody detection in organ transplantation | Q37389868 | ||
| Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient | Q37425991 | ||
| Solid phase assays for HLA antibody detection in clinical transplantation | Q37600156 | ||
| Antiallograft antibodies: relevance, detection, and monitoring | Q37629536 | ||
| Current methodologies for detecting sensitization to HLA antigens | Q37888428 | ||
| Impact of donor-specific HLA antibodies in transplantation, a review of the literature published in the last three years. | Q37893118 | ||
| Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet the expectations? | Q39596692 | ||
| Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens | Q39900257 | ||
| Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients | Q39951249 | ||
| Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation | Q39979381 | ||
| Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development | Q40110625 | ||
| Sharing kidneys across donor-service area boundaries with sensitized candidates can be influenced by HLA C. | Q42643050 | ||
| HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss | Q43288501 | ||
| The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients | Q43856835 | ||
| Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes | Q44598524 | ||
| Detection and specification of noncomplement binding anti-HLA alloantibodies | Q45158306 | ||
| Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts | Q45287212 | ||
| Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. | Q46060462 | ||
| Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? | Q46630985 | ||
| Antibodies against HLA-DQ alpha-chain and their role in organ transplantation | Q47694614 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| Luminex donor-specific crossmatches | Q47802395 | ||
| Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant | Q47989417 | ||
| Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. | Q47989446 | ||
| Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor | Q47990514 | ||
| Simultaneous HLA Class I and Class II antibodies screening with flow cytometry | Q47995527 | ||
| Specific "intra-allele" and "intra-broad antigen" human leukocyte antigen alloantibodies in kidney graft transplantation. | Q50576365 | ||
| Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. | Q50618048 | ||
| C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. | Q50899566 | ||
| Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. | Q51094516 | ||
| ELISA methods detect HLA antibodies with variable sensitivity. | Q51197852 | ||
| HLA antibody identification with single antigen beads compared to conventional methods. | Q51303028 | ||
| [C4d]FlowPRA screening--a specific assay for selective detection of complement-activating anti-HLA alloantibodies. | Q51443894 | ||
| Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. | Q51621019 | ||
| Unexpected anti-HLA-DR and -DQ alloantibodies after nephrectomy of an HLA-DR and -DQ identical first renal transplant. | Q51738986 | ||
| Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. | Q51820209 | ||
| Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. | Q51959096 | ||
| Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? | Q53261912 | ||
| Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. | Q53310440 | ||
| Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. | Q53659700 | ||
| Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome. | Q54338277 | ||
| Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study | Q58863629 | ||
| Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts | Q62513513 | ||
| Enzyme-linked immunoassay for anti-HLA antibodies--an alternative to panel studies by lymphocytotoxicity | Q70529151 | ||
| Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity | Q72063303 | ||
| Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine | Q80068380 | ||
| DP reactive antibody in a zero mismatch renal transplant pair | Q80485052 | ||
| Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients | Q81137752 | ||
| In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts | Q81414145 | ||
| Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates | Q81547543 | ||
| Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads | Q81600356 | ||
| HLA-DP antibodies before and after renal transplantation | Q82491198 | ||
| Effect of pretransplant human leukocyte antigen antibodies detected by solid-phase assay on heart transplant outcomes | Q82978588 | ||
| The utility of comprehensive assessment of donor specific anti-HLA antibodies in the clinical management of pediatric kidney transplant recipients | Q83100755 | ||
| Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients | Q83149390 | ||
| C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection | Q84069012 | ||
| Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools | Q84070564 | ||
| Which human leukocyte antigen antibodies are really clinically relevant? | Q84182828 | ||
| Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation | Q84336784 | ||
| Detailed examination of HLA antibody development on renal allograft failure and function | Q84476021 | ||
| Donor-specific antibody detection: comparison of single antigen assay and Luminex crossmatches | Q84567672 | ||
| Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha | Q84580087 | ||
| Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 | ||
| On solid-phase antibody assays | Q84973210 | ||
| Antihuman Leukocyte Antigen–Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches | Q85159536 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 373-381 | |
| P577 | publication date | 2012-05-03 | |
| P1433 | published in | Clinical and experimental nephrology | Q26842022 |
| P1476 | title | Luminex and antibody detection in kidney transplantation | |
| P478 | volume | 16 |
| Q46621729 | Anti-human leukocyte antigen antibodies are present in blood of blood donors: is therapy with blood preparations safe for graft recipients? |
| Q57489325 | C3d Assay in Correlation With Single Antigen Bead Assay for Human Leukocyte Antigen Antibodies |
| Q34080938 | Clinical outcomes among renal transplant recipients with pre-transplant weakly reactive donor-specific antibodies |
| Q38217273 | Complement as a multifaceted modulator of kidney transplant injury |
| Q85281022 | Effect of Different Sensitization Events on HLA Alloimmunization in Kidney Transplantation Candidates |
| Q64884342 | Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients. |
| Q26995453 | Effects of complement activation on allograft injury |
| Q38929359 | From HLA typing to anti-HLA antibody detection and beyond: The road ahead |
| Q38103831 | Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers |
| Q35145920 | Human leukocyte antigen matching in heart transplantation: systematic review and meta-analysis. |
| Q38246225 | Human leukocyte antigens and alloimmunization in heart transplantation: an open debate |
| Q42243081 | Impact of flow cytometry crossmatch B-cell positivity on living renal transplantation |
| Q88186292 | Impact of pretransplant exposure to allosensitization factors generating HLA antibodies in the Luminex era |
| Q28660815 | Long-term outcomes of children after solid organ transplantation |
| Q35885244 | Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience. |
| Q51454635 | Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. |
| Q30456482 | Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine |
Search more.